Association between oestrogens receptor expressions in breast cancer and comorbidities: a cross-sectional, population-based study.
BACKGROUND
Breast cancer with oestrogen receptor expression is common in older women. Several factors, such as age and reproductive hormone exposure, have been associated with oestrogen receptor expression in breast cancer. However, the association between comorbidities and the oestrogen receptor expression has been poorly studied. We hypothesized that there was an association between burden comorbidity and breast cancer with oestrogen receptor expression in older women.


OBJECTIVE
To determine whether oestrogen receptor expression in breast cancer was associated with burden comorbidity in community-dwelling women.


METHODS
A total of 1,707 women with breast cancer registered on the list of a breast cancer registry were included. The recorded data included: age, Charlson Comorbidity Index score≥1, breast cancer characteristics (coded according to the International Classification of Diseases for Oncology), and breast cancer pathological stage (the pathological-tumour-node-metastasis, Scarff Bloom Richardson, and hormonal status of oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor).


RESULTS
Breast cancer with oestrogen receptor expression was identified in 1,378 patients (80·7%). The fully-adjusted logistic regression showed that oestrogen receptor expression was associated with Charlson Comorbidity Index score≥1 (odds ratio [OR] = 1·91,95%confidence interval [CI] = [1.01-3.61], P = 0·048), progesterone receptor expression (OR = 16·64, 95%CI = [11.62-23.81], P<0·001), human epidermal growth factor receptor (OR = 0·54, 95%CI = [0.34-0.84], P = 0·007), age (OR = 1.02, 95%CI = [1.00-1.03], P = 0.008), Scarff Bloom Richardson grade II and grade III (OR = 0·21with 95%CI = [0.10-0.44] and OR = 0·06 with 95%CI = [0.03-0.12], P<0·001).


CONCLUSIONS
Our findings provide new data showing an independent positive association between burden comorbidity and breast cancer with oestrogen receptor expression. This result confirms that evaluation of oestrogen receptor expression in breast cancer should not be limited to hormonal factors stratified by age.
Department of Therapeutic, EA 1156-12, Division of Geriatric Medicine, Nantes University Hospital, Nantes, France.
Laure
L
de Decker
Ouest Cancer Institut, UMR-INSERM U892, Nantes, France.
Mario
M
Campone
Department of Departmental Geriatrics, Marseille, France.
Frederique
F
Retornaz
Department of Therapeutic, EA 1156-12, Division of Geriatric Medicine, Nantes University Hospital, Nantes, France.
Gilles
G
Berrut
Department of Neuroscience, UPRES EA 4638, UNAM, Division of Geriatric Medicine, Angers University Hospital, Angers, France.
Anastasia
A
Kabeshova
Ouest Cancer Registry, Nantes, France.
Florence
F
Molinié
Department of Neuroscience, UPRES EA 4638, UNAM, Division of Geriatric Medicine, Angers University Hospital, Angers, France.
Olivier
O
Beauchet
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000150:complications* / Q000235:genetics / Q000378:metabolism*; D015897:Comorbidity; D003430:Cross-Sectional Studies; D066246:ErbB Receptors / Q000378:metabolism; D047628:Estrogen Receptor alpha / Q000378:metabolism*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016017:Odds Ratio; D011980:Receptors, Progesterone / Q000378:metabolism; D012042:Registries; D012307:Risk Factors
C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D011980:Receptors, Progesterone; D066246:ErbB Receptors